associ disease-fre surviv percent ideal dose adjuv breast chemotherapi relationship percent ideal dose disease-fre surviv stage II iii patient breast adjuv chemotherapi trial consist cyclophosphamid methotrex cmf previou work result dose-respons relationship improv disease-fre surviv patient dose adjuv chemotherapi major critic analysi bia bia patient therapi month dose-respons relationship causal appar differ disease-fre surviv dose group recurr first year patient dose chemotherapi 